Payment overview · 2025
General Payments
$1,202.28
51 reported records · 12 companies
Healthcare provider profile · identity verified
Soling Li, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · SUNRISE, FL · NPI 1649233925
Verified facts
What the public records show
CMS Open Payments records show Soling Li, D.O. received $1,202.28 in general payments during 2025 across 51 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $327.09 | 27.2% | 9 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $254.37 | 21.2% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $163.65 | 13.6% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.05 | 6.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $75.81 | 6.3% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.80 | 6.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $70.52 | 5.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.18 | 3.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.07 | 3.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $26.92 | 2.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.50 | 2.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.32 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,191.73 | 49 |
| Education | $10.55 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $163.65 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $156.45 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $124.62 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.05 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $76.05 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.80 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $70.52 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $70.52 | 4 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $46.18 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.07 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.57 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.50 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 58 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 506 | 161 |
| Metformin Hcl | Metformin Hcl | 468 | 154 |
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 133 |
| Losartan Potassium | Losartan Potassium | 369 | 122 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 364 | 111 |
| Meloxicam | Meloxicam | 347 | 167 |
| Clonazepam | Clonazepam | 342 | 113 |
| Diclofenac Sodium | Diclofenac Sodium | 301 | 119 |
| Alprazolam | Alprazolam | 243 | 43 |
| Levothyroxine Sodium | Levothyroxine Sodium | 242 | 81 |
| Methylprednisolone | Methylprednisolone | 217 | 150 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 79 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 199 | 141 |
| Omeprazole | Omeprazole | 183 | 69 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 171 | 86 |
| Alendronate Sodium | Alendronate Sodium | 162 | 55 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 134 | 25 |
| Lisinopril | Lisinopril | 130 | 45 |
| Baclofen | Baclofen | 124 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 39 |
| Oxycodone Hcl | Oxycodone Hcl | 119 | 14 |
| Famotidine | Famotidine | 117 | 63 |
| Azithromycin | Azithromycin | 105 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 44 |
| Gabapentin | Gabapentin | 103 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 35 |
| Pantoprazole Sodium | Pantoprazole Sodium | 98 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 97 | 33 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 95 | 45 |
| Ibuprofen | Ibuprofen | 94 | 29 |
| Montelukast Sodium | Montelukast Sodium | 93 | 37 |
| Tramadol Hcl | Tramadol Hcl | 89 | 37 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 41 |
| Lovastatin | Lovastatin | 86 | 27 |
| Temazepam | Temazepam | 76 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 75 | 30 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 74 | 25 |
| Carvedilol | Carvedilol | 73 | 24 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 27 |
| Potassium Chloride | Potassium Chloride | 73 | 24 |
| Irbesartan | Irbesartan | 67 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 67 | 30 |
| Glipizide Er | Glipizide | 59 | 23 |
| Folic Acid | Folic Acid | 58 | 18 |
| Ozempic | Semaglutide | 58 | 16 |
| Clindamycin Hcl | Clindamycin Hcl | 57 | 41 |
| Diazepam | Diazepam | 57 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 19 |
| Allopurinol | Allopurinol | 56 | 18 |
| Meclizine Hcl | Meclizine Hcl | 56 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 17 |
| Albuterol Sulfate | Albuterol Sulfate | 54 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | 21 |
| Celecoxib | Celecoxib | 53 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 19 |
| Atenolol | Atenolol | 50 | 16 |
| Fenofibrate | Fenofibrate | 50 | 17 |
| Finasteride | Finasteride | 50 | 16 |
| Lorazepam | Lorazepam | 50 | 12 |
| Fluconazole | Fluconazole | 49 | 40 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 19 |
| Valacyclovir | Valacyclovir Hcl | 49 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 48 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 48 | 21 |
| Glyxambi | Empagliflozin/Linagliptin | 46 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 13 |
| Eliquis | Apixaban | 45 | suppressed |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 43 | 24 |
| Farxiga | Dapagliflozin Propanediol | 42 | 13 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 42 | 38 |
| Jardiance | Empagliflozin | 41 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 40 | 26 |
| Furosemide | Furosemide | 38 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | 15 |
| Metronidazole | Metronidazole | 34 | 31 |
| Simvastatin | Simvastatin | 32 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | 13 |
| Nifedipine Er | Nifedipine | 29 | 13 |
| Ondansetron Odt | Ondansetron | 28 | 15 |
| Prednisone | Prednisone | 28 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 24 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Repaglinide | Repaglinide | 24 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 24 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 23 | 12 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 23 | 15 |
| Glipizide | Glipizide | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 18 |
| Valsartan | Valsartan | 22 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Dexamethasone | Dexamethasone | 19 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Carisoprodol | Carisoprodol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 12 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Vemlidy | Tenofovir Alafenamide | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,202.28 · 51 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, KRYSTEXXA, Kerendia, MOUNJARO, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, Veozah, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error